Revaccination following suspected vaccine-triggered hypersensitivity reactions: experience of a tertiary care centre

Main Article Content

Aysegul Ertugrul
Ozlem Cavkaytar
İlknur Bostanci
Serap Özmen


allergy, child, hypersensitivity, immunisation, paediatric, vaccine.


Introduction and objectives: Suspected hypersensitivity reactions (HRs) associated with vaccines are frequently reported, but confirmed cases of vaccine-triggered HRs are rare. Suspected HRs should be distinguished from actual HRs. The aims of this study are to identify the rate of actual vaccine-triggered hypersensitivity in patients who were referred to the paediatric allergy clinic due to a suspected HR and to explore the rate of revaccination in a real clinical setting.

Materials and methods: A retrospective study was performed with a group of preschool children who were evaluated by skin and/or provocation tests (PTs) for the suspected HRs following vaccination.

Results: A total of 26 paediatric patients (61.5% male; median age 9 months) with a previous history of suspected vaccine-triggered HR were included. In this group, 69.2% and 38.5% of the patients had a pre-existing atopic disease and an immediate reaction (emerging <1 hour after vaccine administration), respectively. Skin rash was the most frequent clinical presentation (96.1%). Vaccine-triggered anaphylaxis was reported in six patients (23.1%). Measles-mumps-rubella was the most frequently suspected vaccine causing HRs. The skin test positivity with the suspected vaccine was 4%, whereas PTs revealed no reaction after reimmunisation in 76.9% (20/26) of the study participants tested.

Conclusions: Most incidents of skin rashes after immunisation are not suggestive of actual HRs. The results in the current study showed that the majority of the patients presenting with suspected HRs tolerated revaccination, including those with a previous history of suspected anaphylaxis. Revaccination of these patients is safe with adequate precautions. It is absolutely essential to be equipped for the management of anaphylaxis.

Abstract 633 | PDF Downloads 197 HTML Downloads 191 XML Downloads 27


1. Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available from: [Accessed 04 May 2020].

2. Zafack JG, De Serres G, Rouleau I, Gariépy MC, Gagnon R, Drolet JP, et al. Clinical approach used in medical consultations for allergic-like events following immunization: Case series report in relation to practice guidelines. J Allergy Clin Immunol Pract. 2017;5:718–27.e1. 10.1016/j.jaip.2016.09.048

3. Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC, Gomes E, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28:628–40. 10.1111/pai.12762

4. Baxter CM, Clothier HJ, Perrett KP. Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia. Hum Vaccin Immunother. 2018;14:2088–92. 10.1080/21645515.2018.1460293

5. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al. Anaphylaxis: Guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69:1026–45. 10.1111/all.12437

6. Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B. Can the Brighton collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine. 2010;28:4487–98. 10.1016/j.vaccine.2010.04.041

7. Hanifin JM. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl). 1980;92:44–7.

8. 2020# GINA report, global strategy for asthma management and prevention. Available from: [Accessed 04 May 2020].

9. Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Beyer K, Bindslev-Jensen C, et al. EAACI food allergy and anaphylaxis guidelines: Diagnosis and management of food allergy. Allergy. 2014;69:1008–25. 10.1111/all.12405; 10.1111/all.12441; 10.1111/all.12398; 10.1111/all.12429

10. Kelso JM, Li JT, Nicklas RA, Blessing-Moore J, Cox L, Lang DM, et al. Adverse reactions to vaccines. Ann Allergy Asthma Immunol. 2009;103(4 Suppl 2):S1–S14. 10.1016/S1081-1206(10)60350-X

11. Wood R, Setse R, Halsey N. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol. 2007;120:478–81. 10.1016/j.jaci.2007.04.035

12. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130:25–43. 10.1016/j.jaci.2012.04.003

13. Childhood immunization schedule of the Ministry of Health of Turkish Republic. T.C. Sağlık Bakanlığı Çocukluk Dönemi Aşı Takvimi. Available from: [Accessed 04 May 2020].

14. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137:868–78. 10.1016/j.jaci.2015.07.048

15. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112:815–20. 10.1542/peds.112.4.815

16. Cheung A, Choo S, Perrett KP. Vaccine allergy? Skin testing and challenge at a Tertiary Pediatric Hospital in Melbourne, Australia. J Allergy Clin Immunol Pract. 2019;7(5):1541–49. 10.1016/j.jaip.2019.01.025

17. Kumru Ş, Yalnızoğlu Ç, Topal S, Altınkaynak S. The relationship between ımmunization status and socio-demographic factors of adolescents. Hemşirelikte Araştırma Geliştirme Dergisi. 2018;20:33–43.

18. Rouleau I, De Serres G, Drolet JP, Skowronski DM, Ouakki M, Toth A, et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.Vaccine. 2013;31:5989–96. 10.1016/j.vaccine.2013.10.033

19. Piñones M, Landaeta M, Bustos P, Toche P, Morales P, Escobar C, et al. Hypersensitivity reactions to measles-mumps-rubella vaccine in patients with IgE-mediated CM allergy. J Allergy Clin Immunol Pract. 2020;8:349–51. 10.1016/j.jaip.2019.06.040